
    
      OUTLINE: Participants living with HIV are randomized to one of three arms. HIV-negative
      participants are assigned to a fourth arm.

      ARM 1: Participants living with HIV receive recombinant human papillomavirus nonavalent
      vaccine intramuscularly (IM) at enrollment, and at 2 and 6 months. Participants also receive
      recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.

      ARM 2: Participants living with HIV receive recombinant human papillomavirus nonavalent
      vaccine IM at enrollment and at 6 months. Participants also receive recombinant human
      papillomavirus nonavalent vaccine booster dose IM at 30 months.

      ARM 3: Participants living with HIV receive recombinant human papillomavirus nonavalent
      vaccine IM at enrollment. Participants also receive recombinant human papillomavirus
      nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus
      nonavalent vaccine completion dose IM at 30 months.

      ARM 4: Participants without HIV receive recombinant human papillomavirus nonavalent vaccine
      IM at enrollment. Participants also receive recombinant human papillomavirus nonavalent
      vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine
      completion dose IM at 30 months.
    
  